Next-Generation Sequencing Reveals a Very Low Prevalence of Deleterious Mutations of Homologous Recombination Repair Genes and Homologous Recombination Deficiency in Ovarian Clear Cell Carcinoma

被引:4
|
作者
Liu, Hangqi [1 ]
Zhang, Zhiwen [1 ]
Chen, Longyun [1 ]
Pang, Junyi [1 ]
Wu, Huanwen [1 ]
Liang, Zhiyong [1 ]
机构
[1] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Mol Pathol Res Ctr, Dept Pathol,State Key Lab Complex Severe & Rare D, Beijing, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2022年 / 11卷
基金
中国国家自然科学基金;
关键词
ovarian clear cell carcinoma; homologous recombination repair gene; homologous recombination deficiency; molecular classification; next-generation sequencing; EXPRESSION; VARIANTS;
D O I
10.3389/fonc.2021.798173
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Ovarian clear cell carcinoma (OCCC) is aggressive and drug-resistant. The prevalence of homologous recombination repair (HRR) gene mutations and homologous recombination deficiency (HRD) remains largely unknown. It is also not clear whether the commonly used molecular-based classification for endometrial carcinoma (EC) is potentially applicable in OCCC. In this study, surgically resected samples were collected from 44 patients with OCCC. Genomic alterations were determined using next-generation sequencing. HRD was estimated by genomic instability. Of 44 patients with OCCC, two (4.5%) harbored likely pathogenic mutations in HRR genes. Notably, no pathogenic or likely pathogenic mutations were found in BRCA1/2. A total of 24 variants of uncertain significance (VUS) in HRR-related genes occurred in 18 (40.9%) patients. HRD was observed in only one case (2.3%). In addition, TP53 mutation and microsatellite instability-high (MSI-H) were identified in three patients (6.8%) and in one patient (2.3%), respectively. TP53 mutation was significantly associated with disease-free survival and overall survival. No POLE mutations were found. In conclusion, our results revealed a very low prevalence of HRR gene mutations and HRD in OCCC. Moreover, TP53 mutations and MSI-H are uncommon, while POLE mutations are extremely rare in OCCC. Our findings indicate that the evaluation of HRR gene mutations, HRD status, POLE mutations, and MSI-H may have limited clinical significance for OCCC treatment and prognostic stratification.
引用
收藏
页数:9
相关论文
共 50 条
  • [11] Homologous recombination deficiency serves as a prognostic biomarker in clear cell renal cell carcinoma
    He, Liping
    Gao, Feng
    Zhu, Jingyu
    Xu, Qiaoping
    Yu, Qiqi
    Yang, Mei
    Huang, Yasheng
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2023, 26 (03)
  • [12] Prevalence and Prognostic Relevance of Homologous Recombination Repair Gene Mutations in Uterine Serous Carcinoma
    Dong, Lin
    Wang, Tingting
    Li, Ning
    Yao, Hongwen
    Ying, Jianming
    Wu, Lingying
    Yuan, Guangwen
    CELLS, 2022, 11 (22)
  • [13] TP53-specific mutations serve as a potential biomarker for homologous recombination deficiency in breast cancer: a clinical next-generation sequencing study
    Huang, Yongsheng
    Ren, Shuwei
    Ding, Linxiaoxiao
    Jiang, Yuanling
    Luo, Jiahuan
    Huang, Jinghua
    Yin, Xinke
    Zhao, Jianli
    Fu, Sha
    Liao, Jianwei
    PRECISION CLINICAL MEDICINE, 2024, 7 (02)
  • [14] Clinical relevance of double heterozygosity revealed by next-generation sequencing of homologous recombination repair pathway genes in South African breast cancer patients
    van der Merwe, Nerina C.
    Buccimazza, Ines
    Rossouw, Bianca
    Araujo, Monica
    Ntaita, Kholiwe S.
    Schoeman, Mardelle
    Vorster, Karin
    Napo, Kgabo
    Kotze, Maritha J.
    Oosthuizen, Jaco
    BREAST CANCER RESEARCH AND TREATMENT, 2024, 207 (02) : 331 - 342
  • [15] Pure primary ovarian squamous cell carcinoma with homologous recombination deficiency: a case report
    Ogimoto, Keisuke
    Kitai, Miho
    Ota, Takehito
    Nakanishi, Takaaki
    Imai, Yukihiro
    Sakuma, Toshiko
    Sudo, Tamotsu
    Yamaguchi, Satoshi
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2024, 45 (02) : 158 - 162
  • [16] Next-generation sequencing-based regression algorithm to determine homologous recombination deficiency scores in a pan-cancer cohort
    Kim, S.
    Han, M-R.
    Oh, E-Y.
    Choi, Y. J.
    Bak, S.
    ANNALS OF ONCOLOGY, 2023, 34 : S1179 - S1179
  • [17] Next-generation sequencing-based regression algorithm to determine homologous recombination deficiency scores in a pan-cancer cohort
    Choi, Boram
    Choi, Youn Jin
    CANCER RESEARCH, 2024, 84 (06)
  • [18] Homologous recombination repair somatic/germline mutation detection in plasma by next-generation sequencing in Chinese solid tumor patients.
    Zhu, Wei
    Chen, Hui
    Zhang, Bei
    Zhao, Xiaochen
    Bai, Yuezong
    CANCER RESEARCH, 2021, 81 (13)
  • [19] Genomic scar signatures associated with homologous recombination deficiency predict adverse clinical outcomes in patients with ovarian clear cell carcinoma
    Chao, Angel
    Lai, Chyong-Huey
    Wang, Tzu-Hao
    Jung, Shih-Ming
    Lee, Yun-Shien
    Chang, Wei-Yang
    Yang, Lan-Yang
    Ku, Fei-Chun
    Huang, Huei-Jean
    Chao, An-Shine
    Wang, Chin-Jung
    Chang, Ting-Chang
    Wu, Ren-Chin
    JOURNAL OF MOLECULAR MEDICINE-JMM, 2018, 96 (06): : 527 - 536
  • [20] Genomic Profiling Reveals Germline Predisposition and Homologous Recombination Deficiency in Pancreatic Acinar Cell Carcinoma
    Mandelker, Diana
    Marra, Antonio
    Zheng-Lin, Binbin
    Selenica, Pier
    Blanco-Heredia, Juan
    Zhu, Yingjie
    Gazzo, Andrea
    Wong, Donna
    Yelskaya, Zarina
    Rai, Vikas
    Somar, Joshua
    Ostafi, Silvana
    Mehta, Nikita
    Yang, Ciyu
    Li, Yirong
    Brown, David N.
    da Silva, Edaise M.
    Pei, Xin
    Linkov, Irina
    Terraf, Panieh
    Misyura, Maksym
    Ceyhan-Birsoy, Ozge
    Ladanyi, Marc
    Berger, Michael
    Pareja, Fresia
    Stadler, Zsofia
    Offit, Kenneth
    Riaz, Nadeem
    Park, Wungki
    Chou, Joanne
    Capanu, Marinela
    Koehler, Maria
    Rosen, Ezra
    O'Reilly, Eileen M.
    Reis-Filho, Jorge S.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (33) : 5151 - +